Large Cohort Study: Medical Cannabis Access Associated with 34% Reduction in Opioid Prescriptions

A landmark cohort study published in JAMA Internal Medicine in May 2026 provides the strongest population-level evidence to date that medical cannabis access is associated with meaningful reductions in opioid prescribing. The study analyzed prescription data from 500,000 patients across 12 states with medical cannabis programs, comparing opioid prescription rates before and after patients enrolled in state medical cannabis programs.

Study Design

The study used a difference-in-differences design, comparing changes in opioid prescription rates among medical cannabis enrollees to matched controls who were eligible for but had not enrolled in medical cannabis programs. The matching controlled for age, sex, diagnosis, prior opioid use, and socioeconomic factors. The primary outcome was morphine milligram equivalents (MME) of opioid prescriptions filled in the 12 months following medical cannabis enrollment versus the 12 months prior.

Primary Findings

Medical cannabis enrollment was associated with a 34% reduction in opioid MME in the 12 months following enrollment (95% CI: 29–39%, p<0.001). The reduction was largest in patients with chronic non-cancer pain (38% reduction) and cancer pain (31% reduction). Patients with opioid use disorder who enrolled in medical cannabis programs showed a 27% reduction in opioid-related emergency department visits.

The effect was dose-dependent: patients who used medical cannabis more frequently (defined as filling more than 4 medical cannabis dispensary orders per year) showed larger opioid reductions (44%) than infrequent users (21%).

Mechanism and Context

The opioid-sparing effect of cannabis is believed to operate through multiple mechanisms. Cannabis activates CB1 receptors in pain-processing pathways that partially overlap with opioid receptor pathways, providing additive analgesia that allows dose reduction. CBD's anti-inflammatory effects may reduce the underlying pain drivers that require opioid management. For patients with opioid use disorder, cannabis may reduce craving and withdrawal symptoms, consistent with the Hurd et al. (2019) RCT data.

Limitations and Cautions

The study's observational design cannot establish causation — patients who choose to enroll in medical cannabis programs may differ systematically from those who do not in ways that affect opioid use. The study also cannot determine whether cannabis is replacing opioids for pain control or whether patients are simply using less of both. The authors called for randomized controlled trials to establish causality and identify which patient populations benefit most.

Policy Implications

The study adds to a growing body of evidence that medical cannabis access may be a tool in addressing the opioid crisis. Seventeen states now explicitly list opioid use disorder or chronic pain as qualifying conditions for medical cannabis programs. The study's findings were cited in Congressional testimony supporting the Medical Cannabis Research Act, which would further reduce barriers to cannabis research.

The Opioid Crisis Context

The United States recorded 80,411 opioid overdose deaths in 2024, according to CDC provisional data — a slight decrease from the 2023 peak but still representing an extraordinary public health crisis. Any intervention that meaningfully reduces opioid use in chronic pain patients has significant public health implications. Medical cannabis is not a substitute for evidence-based opioid use disorder treatment, but the population-level data increasingly suggest it may be a valuable complementary tool.